ESMO Releases New Patient Guide in NSCLC

A comprehensive new edition presents the latest information in early, locally advanced and metastatic NSCLC

ESMO is pleased to present a new ESMO Patient Guide in non-small cell lung cancer (NSCLC), an important new edition in our Patient Guide Series.

Reflecting key developments in the field, this new ESMO Patient Guide in NSCLC delivers the following new information compared to the previous edition:

  • Epidemiology of NSCLC updated to reflect 2018 data
  • Text added to summarise the results of the NELSON screening trial
  • TNM staging information updated in line with AJCC/UICC 8th edition
  • Section on the biological testing of tumour specimens updated to include BRAF and ROS1 testing
  • Section added on shared decision-making
  • Immunotherapy added to the overview of treatment types
  • Treatment options updated to reflect current guidelines:
    • Durvalumab added as an option for PD-L1-positive locally advanced disease following CRT
    • Pembrolizumab added as a first-line option in combination with chemotherapy for metastatic disease
    • Osimertinib and erlotinib + bevacizumab added as first-line options for EGFR mutated metastatic disease
    • Dabrafenib + trametinib added as first-line treatment for metastatic disease with BRAF V600E mutation
    • Ceritinib and alectinib added as first-line options for metastatic disease with ALK rearrangement
    • Crizotinib added as first-line treatment for metastatic disease with ROS1 rearrangement
    • Atezolizumab added as a second-line option for metastatic disease
    • Brigatinib and lorlatinib added as second-line options for metastatic disease with ALK rearrangement
  • Clinical trials section updated to include lorlatinib, dacomitinib and combinations of existing treatments
  • Section added on supplementary interventions, including supportive, palliative, survivorship and end-of-life care
  • Side effects section updated to include new treatments
  • Text added on the importance of exercise and a healthy lifestyle

The previous edition of this guide was translated into 8 languages through the kind support of national medical associations and patient advocacy organisations. The availability of translations in languages spoken across continents ensured the guide was well received in many countries worldwide. We welcome support for the translation and dissemination of this new and updated version. To express an interest in providing a translation, please contact ESMO.

This guide has been developed and reviewed by an editorial board composed of:

Representatives of the European Society for Medical Oncology (ESMO): David Planchard; Silvia Novello; Solange Peters; Raffaele Califano; Jean-Yves Douillard; Francesca Longo; Claire Bramley; and Svetlana Jezdic

Representatives of the European Oncology Nursing Society (EONS): Anita Margulies; and Roisin Lawless

Patient advocate from Lung Cancer Europe (LuCE) and Women Against Lung Cancer in Europe (WALCE):Stefania Vallone

ESMO Patient Guides in other topics are available here. The medical information in all of our Patient Guides is based on the ESMO Clinical Practice Guidelines.